CJC-1295 + Ipamorelin: The Growth Hormone Stack — Clinical Evidence, Dosing & What to Expect

Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

The CJC-1295 and Ipamorelin combination is the most widely prescribed growth hormone peptide stack in anti-aging and regenerative medicine clinics. By combining a long-acting GHRH analog with a selective growth hormone secretagogue, this stack produces sustained, physiological elevations in GH and IGF-1 without the side effects of exogenous growth hormone.

What Are CJC-1295 and Ipamorelin?

CJC-1295: The Long-Acting GHRH Analog

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 29 amino acids. CJC-1295 with Drug Affinity Complex (DAC) binds to serum albumin, extending its half-life to approximately 6-8 days.

Teichman et al. (2006) demonstrated that subcutaneous CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults Teichman et al., 2006.

Ipamorelin: The Selective Growth Hormone Secretagogue

Ipamorelin is a pentapeptide that activates the growth hormone secretagogue receptor (GHSR). Raun et al. (1998) established it as a potent and selective GH secretagogue that did not release ACTH or cortisol significantly Raun et al., 1998.

The Synergy: Why Combine Them?

Yin et al. (2014) highlighted the synergistic effect when GHRH and GHSR agonists are co-administered Yin et al., 2014.

CJC-1295 acts as the “amplifier” — increasing somatotroph capacity via cAMP/PKA signaling.

Ipamorelin acts as the “trigger” — providing pulsatile GH release via PLC/IP3/DAG pathway.

Together, they produce GH elevations 2-3x greater than either peptide alone.

Clinical Evidence

Growth Hormone and IGF-1 Elevation

A single dose of CJC-1295 produced a 2-10 fold GH increase sustained for up to 6 days, with IGF-1 elevated for 9-11 days Teichman et al., 2006.

Safety Profile

Sigalos and Pastuszak (2018) highlighted that GH secretagogues show promise but need more long-term studies Sigalos & Pastuszak, 2018. A 2026 review noted limited evidence for clinical use in humans Mayfield et al., 2026.

---

> Considering adding this to your protocol? Work with licensed providers who understand peptide therapy. Telegenix offers personalized protocols based on your bloodwork and goals. Schedule your free consultation today.

---

CJC-1295 + Ipamorelin vs. Other GH Therapies

| Feature | CJC-1295 + Ipamorelin | HGH (Somatropin) | MK-677 | Sermorelin |

|---|---|---|---|---|

| Mechanism | Dual GHRH + GHSR | Direct GH replacement | Oral GHSR agonist | GHRH analog |

| GH Pattern | Pulsatile (physiological) | Flat (supraphysiological) | Sustained | Pulsatile |

| IGF-1 Increase | 1.5-3x baseline | 2-5x baseline | 1.5-2x baseline | 1.2-2x baseline |

| Cortisol Impact | Minimal | None | Mild increase | None |

| Feedback Suppression | No | Yes | Minimal | No |

Dosing Protocols

| Protocol | CJC-1295 Dose | Ipamorelin Dose | Frequency | Duration |

|---|---|---|---|---|

| Anti-Aging | 100 mcg | 200 mcg | Once daily (before bed) | 12-16 weeks |

| Body Composition | 100 mcg | 300 mcg | 1-2x daily | 12-16 weeks |

| Recovery | 100 mcg | 200-300 mcg | 2x daily | 8-12 weeks |

| CJC-1295 DAC | 2 mg weekly | 200 mcg daily | See notes | 12-16 weeks |

Timing: Best on an empty stomach before bed. Avoid eating for 30-60 minutes after injection, as insulin blunts GH release.

What to Expect: Timeline

| Timeframe | Expected Effects |

|---|---|

| Week 1-2 | Improved sleep quality, vivid dreams |

| Week 3-4 | Increased energy, faster recovery |

| Week 6-8 | Skin quality improvements, body composition changes begin |

| Week 10-12 | Measurable fat loss, lean mass gains, improved IGF-1 on bloodwork |

| Week 12-16 | Full benefits realized; reassess with bloodwork |

---

> Ready to start a personalized peptide protocol? The licensed providers at Telegenix specialize in peptide therapy and hormone optimization. Book a free consultation to get a protocol tailored to your bloodwork, goals, and biology.

---

Key Takeaways

The CJC-1295 + Ipamorelin stack represents the current gold standard in peptide-based growth hormone optimization. The clinical evidence supports its safety and efficacy for GH and IGF-1 elevation, though long-term human data remains limited.

> Related Comparison: Tesamorelin vs Ipamorelin: GH Peptide Comparison

> Related Comparison: NAD+ vs NMN: Which Longevity Supplement?

> Related Comparison: Sermorelin vs CJC-1295: Complete Comparison

References

  • Teichman SL, et al. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed
  • Raun K, et al. Eur J Endocrinol. 1998;139(5):552-61. PubMed
  • Yin Y, et al. Int J Mol Sci. 2014;15(3):4837-55. PMC
  • Sigalos JT, Pastuszak AW. Sex Med Rev. 2018;6(1):45-53. PMC
  • Mayfield CK, et al. Am J Sports Med. 2026;54(1):223-229. Link
  • ---

    Explore Related Peptides on OnlinePeptideDoctor.com

  • The Wolverine Stack: BPC-157 + TB-500 — Add tissue repair to your GH protocol
  • DSIP: Deep Sleep Peptide — Optimize sleep for maximum GH release
  • NAD+ Therapy: Cellular Energy — Enhance metabolic function alongside GH
  • BPC-157 Arginine Salt — Gut health and recovery support
  • Browse All Peptide Articles — 80+ research-backed articles
  • Disclaimer: This article is for educational and informational purposes only. It is not medical advice. CJC-1295 and Ipamorelin are research peptides not FDA-approved for clinical use.

    ---

    Related Reading

    Explore more in-depth guides on related topics:

  • CJC-1295: What the Science Actually Says — A PubMed-Backed Review
  • CJC-1295 and Ipamorelin: The Growth Hormone Stack Explained
  • Ipamorelin: What the Science Actually Says — A PubMed-Backed Review
  • Sermorelin: What the Science Actually Says — A PubMed-Backed Review
  • MK-677 (Ibutamoren): What the Science Actually Says — A PubMed-Backed Review
  • For a comprehensive overview, see our Complete Guide to Peptide Therapy.

    ---

    Related Articles

  • 10 Peptide Therapy Misconceptions: Setting the Record Straight
  • 2023 Year in Review: The Year the FDA Banned 19 Peptides
  • 2024 Year in Review: FDA Peptide Actions and Legal Battles
  • 2025 Year in Review: FDA Peptide Regulation Highlights